Objectives: To determine if ceftaroline and ceftazidime combined with avibactam are efficacious against pulmonary Mycobacterium avium complex (MAC) disease.
Introduction
Mycobacterium species are naturally resistant to most b-lactam antibiotics, due to production of b-lactamases, reduced affinity of drug targets and limited permeability of the cell wall. [1] [2] [3] The intrinsic b-lactam resistance of Mycobacterium tuberculosis (Mtb) has been attributed to the highly active b-lactamase BlaC and that of Mycobacterium abscessus (Mab) to the b-lactamase Bla Mab . 1, 4, 5 It should therefore be possible to overcome the intrinsic antibiotic resistance by using b-lactamase inhibitors. The b-lactamase inhibitor clavulanate irreversibly inactivates BlaC. 4 In a recent 14 day study in patients with tuberculosis (TB), the use of amoxicillin/clavulanate with the carbapenem meropenem three times a day demonstrated an effect equivalent to the combination of rifampicin, isoniazid and pyrazinamide, showing that b-lactamase inhibition can potentiate antimycobacterial effects of clinical relevance. 6 On the other hand, avibactam is a non-b-lactam b-lactamase inhibitor that inhibits BlaC by forming a carbamyl adduct with the enzyme as well as Bla Mab via reversible formation of a covalent adduct. 7, 8 We recently examined the efficacy of ceftazidime/avibactam for Mtb. 9 However, whilst it is well known that Mtb, Mab, Mycobacterium fortuitum and Mycobacterium smegmatis produce b-lactamases, very little work has examined the more recent b-lactams and newer b-lactamase inhibitors for the treatment of Mycobacterium avium complex (MAC), which causes pulmonary disease in a larger number of patients in the USA than TB. [10] [11] [12] [13] Rather, it is assumed that MAC does not produce b-lactamases, and resistance to b-lactams is via other mechanisms. 14, 15 However, this was likely due to the limitation of the assays used 20 years ago. Using a highly sensitive spectrophotometric method, strains of M. avium were recently shown to possess mild to moderate b-lactamase activity, which was weakly inhibited by sulbactam. 16 The exact type of b-lactamase remains uncharacterized. Among the b-lactam antibiotics, third-and fourth-generation cephalosporins have generally not been examined for efficacy against MAC. The third-generation cephalosporin ceftazidime has been considered to have major gaps in its coverage of Grampositive bacteria in general. Specifically, rapidly growing mycobacteria are resistant to ceftazidime. 17 Thus, PANTA (polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlocillin), used to reduce contamination of mycobacterial sputum cultures by other faster-growing bacteria, has been fortified with ceftazidime (PANTA/ CAZ) in the Mycobacteria Growth Indicator Tube and the BACTEC MGIT 960 system (MGIT). In a study to examine the effect of PANTA versus PANTA/CAZ, time-to-positivity for Mtb and MAC were not altered by ceftazidime; rather the growth index was altered by trimethoprim in MAC and nalidixic acid in Mtb. 18 Thus, ceftazidime itself is not effective against MAC and Mtb. Recently, ceftazidime was combined with avibactam in order to reverse resistance among Gram-negative bacilli. We were interested in examining the anti-MAC effect of ceftaroline, a fourth-generation cephalosporin with excellent activity against Gram-positive bacteria, with and without avibactam. 19, 20 As we were unable to procure avibactam as a lone drug to use in combination with ceftaroline at that time (an issue since resolved), we proceeded instead with the experiment using the combined form of ceftazidime/avibactam that was commercially available, on the premise that ceftazidime would have no effect on MAC as demonstrated in the PANTA experiments. We were pleasantly surprised to be proved wrong.
Materials and methods

Bacterial strain and chemicals
Mycobacterium avium subsp. hominissuis (ATCC 700898) was purchased from the ATCC (Manassas, VA, USA). Stock and propagation of cultures were as described previously. [21] [22] [23] [24] THP-1 monocytes (TIB-202) were purchased from the ATCC. Ceftazidime/avibactam and ceftaroline intended for human intravenous use were obtained from the Baylor University Medical Center pharmacy. Hollow-fibre cartridges were purchased from FiberCell (Frederick, MD, USA).
Screening of cephalosporins against MAC
MAC was grown into logarithmic growth phase (log-phase growth) in Middlebrook 7H9 broth with 10% OADC, herein termed 'broth', at 37 C to an optical density of 0.08 and then diluted to achieve a bacterial density of 10 5 cfu/mL. In the first arm, MAC culture was treated with ceftaroline concentrations of 0, 1, 2, 4, 8, 16, 32, 64, 128 and 256 mg/L in triplicate for 7 days in test tubes at 37 C under 5% CO 2 . Alkaline phosphatase was added to each test tube to achieve a final concentration of 75 IU to facilitate conversion from prodrug to active form. In parallel, ceftaroline at the same concentrations was supplemented with a ceftazidime/avibactam concentration of 58.5/15 mg/L, in triplicate, all other things being equal. Thus, we had a set of test tubes supplemented with the same ceftazidime/avibactam concentration of 58.5/15 mg/L but without ceftaroline as well as a second set of controls with neither ceftaroline nor ceftazidime/avibactam. After 7 days, cultures were washed to remove drug carry over, and then cultured on Middlebrook 7H10 agar at 37 C for 14 days, at which time colonies were counted.
Determination of MIC
Ceftazidime/avibactam MIC was determined using two methods. First, the broth macrodilution method in Middlebrook 7H9 broth as described earlier for linezolid. 24 The second method was broth microdilution. In the microdilution method, 20 lL of ceftazidime/avibactam (3.9:1 ratio) at 10 times the final concentrations was added to 180 lL of bacterial suspension in each microwell. The ceftazidime final concentrations examined were 0, 0.25, 0.5, 1.0, 2, 4, 8, 16, 32, 64 and 128 mg/L, in triplicate. Bacterial suspension was prepared as described above, and co-incubated with the concentrations at 37 C under 5% CO 2 for 7 days, after which 25 lL of 2% Tween 80 was added to each well and visualized after shaking for 10 s in the spectrophotometer. The lowest concentration of ceftazidime/avibactam that inhibited growth as observed with the unaided eye was defined as the MIC.
Ceftazidime/avibactam concentration-effect study against extracellular MAC Log-phase growth MAC at a bacterial density of 10 5 cfu/mL were coincubated with ceftazidime/avibactam (3.9:1 ratio) at ceftazidime concentrations of 0, 12.5, 25, 50, 100, 200, 400 or 800 mg/L in Middlebrook 7H9 broth, in triplicate, for 7 days. After 7 days, the cultures were washed twice to remove drug. The cultures were then processed on Middlebrook 7H10 agar as described above for cfu counts.
Ceftazidime/avibactam concentration-effect study against intracellular MAC
The human-derived THP-1 monocyte cell line growing in 12-well plates in RPMI 1640 and 10% FBS was activated using phorbol myristate acetate (PMA) and became adherent after 72 h, after which it was infected with MAC, as described previously. 24 The cultures were then co-incubated with ceftazidime/avibactam at concentrations of 0, 25, 50, 100, 200, 400, 800 and 1600 mg/L, and incubated for 7 days, after which the drug was washed off twice using warm RPMI. The THP-1 cells were then ruptured, followed by culturing for cfu counts.
Ceftazidime/avibactam dose-effect study in the hollow-fibre system
In order to determine if ceftazidime/avibactam would work against pulmonary MAC at clinically attainable doses, we performed dose-response studies in the HFS-MAC. [21] [22] [23] [24] [25] Non-activated THP-1 monocytes were infected with MAC, as described previously. [21] [22] [23] [24] [25] Next, 20 mL of MAC-infected THP-1 cells was injected into the external compartment of each of the eight HFS-MAC. [20] [21] [22] [23] [24] Ceftazidime/avibactam (3.9:1 ratio) was administered every 8 h for 28 days by computer-programmed syringe pumps via an infusion port into the central compartment, to achieve a half-life of 3 h, and to replicate concentrations achieved in human lungs given ceftazidime/avibactam based on the 33% penetration ratio from blood into epithelial lining fluid. 26 Each HFS-MAC was dosed with ceftazidime/avibactam every 8 h to achieve a proportion of the dosing interval for which concentrations stay above the MIC (fT .MIC ) of 0, 0, 0, 0, 0, 3%, 33% and 90%, based on an exploration of doses up to twice the standard dose. 26 We sampled the central compartments of each HFS-MAC at 2, 5, 8, 10, 13, 16, 18 and 23 h after the first dose. We also sampled the peripheral compartment of each HFS-MAC on days 0, 4, 7, 14, 21 and 28 of treatment to determine cfu/mL.
Ceftazidime/avibactam dose-fractionation study in the HFS-MAC
We performed a dose-fractionation study in the HFS-MAC, but this time used extracellular MAC in which we had no protein or albumin for binding, in order to calculate free-drug exposures. Dosing schemes included dosing to achieve peak concentrations to MIC (C max /MIC) ratios of 1.125, 2.25 and 4.5 mg/L administered either as once every 24 h or every 12 h or every 8 h, with replicate systems treated to achieve a C max /MIC ratio of 0.5625 mg/L administered once a day, and another set to achieve 9 mg/L administered Ceftazidime/avibactam for pulmonary MAC JAC ii37 every 8 h. This dosing scheme was meant to break the collinearity of free drug (f) C max /MIC, AUC/MIC and fT .MIC that would otherwise occur with dose increase.
Ceftazidime/avibactam drug concentration assay
Ceftazidime concentrations in the samples collected from the central compartment of the HFS were analysed by liquid chromatography with tandem mass spectrometry. The assay to measure ceftazidime and avibactam was as described previously. 9 
Pharmacokinetic and pharmacokinetic/ pharmacodynamic analysis
The ceftazidime/avibactam concentrations were modelled using ADAPT 5 software. 27, 28 Both one-and two-compartment models were examined, and the best model chosen using the Akaike Information Criterion, the Bayesian Information Criterion and parsimony. The effect of drug exposure versus effect was examined using the inhibitory sigmoid maximal kill (E max ) model in ADAPT.
Results
As shown in Figure 1 , the inhibitory sigmoid model revealed a ceftaroline E max of 4.87+0.26 log 10 cfu/mL and an exposure mediating 50% of E max (EC 50 ) of 12.97+1.23 mg/L when used alone (r 2 " 0.952). When ceftaroline was used in combination with ceftazidime/avibactam, a different dose-response was observed, characterized by an E max of 4.65+0.37 log 10 cfu/mL, similar to ceftaroline alone, but an EC 50 of 0.01+0.103 mg/L (r 2 " 0.922). Thus, the ceftazidime/avibactam dramatically improved ceftaroline potency, but not efficacy. In addition, Figure 1 shows that in the 'non-treated' zero ceftaroline concentrations which had ceftazidime/avibactam, the bacterial burden was 2.49 log 10 cfu/mL below the control that used no drug at all (ceftazidime/avibactam " 0 mg/L, ceftaroline " 0 mg/L). This suggested that ceftazidime/avibactam on its own had an inhibitory effect on MAC. Therefore, we sought to identify the ceftazidime/avibactam MIC. The ceftazidime MIC (in the presence of avibactam) was 16 mg/L with the broth macrodilution method and 32 mg/L with the broth microdilution method, a 2-fold difference. We adopted the MIC of 16 mg/L.
Next, we performed a formal concentration-effect study of ceftazidime/avibactam against extracellular MAC in test tubes. Inhibitory sigmoid E max modelling results, with ceftazidime concentrations expressed as multiplicity of MIC, are shown in Figure 2(a) . The E max was 3.80+0 log 10 cfu/mL, Hill slope of 1.2+0.19, and the ceftazidime EC 50 was 6.99+1.14 % MIC (r 2 " 0.97). Thus, ceftazidime had considerable efficacy against extracellular MAC. The inhibitory sigmoid E max relationship against intracellular MAC is shown in Figure 2(b) . The E max was 3.60+0.25 log 10 cfu/mL, and the EC 50 was 8.61+0.93 % MIC (r 2 " 0.94), virtually the same as for extracellular MAC. The ceftaroline concentration-effect curve shifted to the left in the presence of ceftazidime/avibactam, thereby improving potency (EC 50 ) more than 1200-fold. The diamond shows the purported ceftazidime/avibactam 'control' which shows a difference from the non-treated control (i.e. no ceftazidime/avibactam and no ceftaroline) of 2.49 log 10 cfu/mL. This strongly suggests that ceftazidime/avibactam on its own could potentially kill MAC. The ceftazidime concentration-effect against extracellular MAC demonstrates good maximum kill, which is calculated relative to non-treated controls of 8.22 log 10 cfu/mL on day 7. However, the kill was below stasis by 0.91 log 10 cfu/mL. (b) A virtually identical effect maximum kill was seen in MAC-infected macrophages, showing that efficacy was independent of culture conditions. However, in this instance the kill below stasis was greater and was 2.19 log 10 cfu/mL.
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In the HFS-MAC, measured ceftazidime and avibactam concentrations were best described using a one-compartment model with first-order input and elimination. The predicted versus observed concentrations with the one-compartment model are shown in Figure 3 , which reveals that the slope was 1.08+0.03, indicating minimal bias (r 2 " 0.95). The mean estimate (%CV) for systemic clearance was 0.035 L/h (1.04%), while that for volume was 0.168 L (1.54%), which translates to a half-life of 3.36+0.06 h. The peak concentrations to MIC ratios achieved in each HFS-MAC are shown in Table 1 . The time-kill plots of different ceftazidime/ avibactam exposures in the HFS-MAC are shown in Figure 4 . An E max of 0.61 log 10 cfu/mL below the day 0 bacterial burden (stasis) was achieved on day 7 with fT .MIC between 34% and 88%. The fT .MIC of 88% kept microbial kill below stasis for up to 14 days of therapy. Thus, ceftazidime/avibactam achieved good microbial kill at exposures achieved by currently utilized clinical doses.
In the dose fractionation HFS-MAC study, avibactam concentrations were found to be .1.0 mg/L for 21% of the dosing interval in the HFS-MAC that received the lowest dose, 31% in the second lowest dose, and .40% in the rest of the HFS-MAC that received antibiotics. The measured ceftazidime concentrations were also best described by a one-compartment model, with predicted versus observed concentrations shown in Figure 5(a) . The model-derived ceftazidime concentration-time profiles are shown as line graphs in Figures 5(b-d) for each dosing schedule, with the measured ceftazidime concentrations shown as circles and squares. The inhibitory sigmoid E max relationships between bacterial burden and the fC max /MIC ratio, fAUC 0-24 /MIC ratio and free-drug fT .MIC are shown in Figure 6 . The free-drug fT .MIC had the lowest Akaike Information Criterion (AIC) scores and highest r 2 on each sampling day. The highest r 2 and lowest AIC score was on day 12, which revealed an EC 50 free-drug fT .MIC of 13.64+3.24, and an EC 80 free-drug fT .MIC of 52%. Maximal kill was 2.40 log 10 cfu/mL below stasis on day 14; 1.0 and 2.0 log 10 cfu/mL kill below stasis was achieved by an fT .MIC of 75% and 100%, respectively.
Discussion
We show here that ceftazidime in combination with the nonb-lactam b-lactamase inhibitor avibactam kills MAC. This finding was unexpected, given that this third-generation cephalosporin was expected to perform poorly against MAC. Indeed, its use in assays such as PANTA for MGIT liquid cultures assumes no efficacy against MAC. The finding brings into question all the other assumptions made to date about the efficacy of first-, second-, third-and fourth-generation cephalosporins against MAC. In the case of ceftaroline, its effect was apparent even without avibactam; however, Figure 1 shows that the avibactam shifted the dose-effect curve, hence the EC 50 , to the left, consistent with improved potency. Indeed, based on 7 day cultures of extracellular MAC in test tubes, ceftaroline E max was 4.87 log 10 cfu/mL, while that of ceftazidime/ avibactam was 3.80 log 10 cfu/mL: this compares to an E max of 1.57 log 10 cfu/mL encountered with the most efficacious agent we have encountered so far, tedizolid, using the same assays at the same timepoint. 25 Based on the results, we call for a general exploration of all cephalosporins with the latest b-lactamase inhibitors for effect against MAC. The exposures in each system were described using the percentage of time that the concentration remains above MIC in a 24 h dosing interval (fT .MIC ). Regimens with low fT .MIC had minimal antimicrobial effect, while those with fT .MIC 34% killed to below the starting inoculum. After day 14, even the highest exposure led to regrowth. This biphasic shape is typical of the loss of effect of monotherapy that is due to resistance emergence. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Macrolides and ethambutol constitute the current standard regimen for treatment of pulmonary MAC disease. 11 The macrolide azithromycin achieved a microbial kill of 0.6 log 10 cfu/mL below stasis in the HFS-MAC model, but at exposures higher than those that can be achieved with the standard dose. 29, 30 Ethambutol, in the same model, failed to contain the bacterial burden to the level of stasis, and bacterial burden actually grew even at the highest ethambutol exposures. 21 Here, we show that the extent of microbial kill below stasis by ceftazidime/avibactam of 2.4 log 10 cfu/mL was higher than for macrolides such as azithromycin, and in the same range as linezolid and tedizolid in the same model. 24, 25, 29 This makes ceftazidime/avibactam a good candidate for further studies on short-course therapy for pulmonary MAC; ceftaroline could even be better but will need to be examined further in the HFS-MAC.
The efficacy of b-lactams such as cephalosporins is driven by fT .MIC . In the FDA docket for dosing of ceftazidime/avibactam, the pharmacokinetic/pharmacodynamic target for ceftazidime/avibactam for Gram-negative bacteria was reported as a free-drug fT .MIC of 40%-50%. For avibactam, the percentage time of freedrug concentrations .1 mg/L required to show an effect in Gramnegative bacilli infection animal models ranged from 20.2% to 40.2%. 31 In the HFS-MAC dose-fractionation study, we identified a free-drug fT .MIC target of ceftazidime 52%, consistent with efficacy of this drug with other pathogens; all regimens that achieved this free-drug fT .MIC 52% target had avibactam concentrations .1 mg/L for .50% of the dosing interval, based on the standard 3.9:1 ratio of the drug currently marketed for clinical use. The idea here was to show that ceftazidime/avibactam at clinically achievable doses kills MAC in our stringent HFS-MAC model. It is known that ceftazidime/avibactam up to clinical doses of 2000/500 mg is well tolerated. 32 While the optimal exposure for combination therapy will depend on the companion drugs, and will be chosen based on synergy and additivity considerations, it will also likely be with clinically achievable doses.
There are some limitations to our study. First, the effect of the MIC distribution could not be taken into account due to the lack of availability of data on the susceptibility of MAC isolates to ceftazidime/avibactam. To our knowledge, no studies have explored the activity of ceftazidime/avibactam against MAC, hence no MIC Deshpande et al.
ii40 distribution data are available. Second, we did not perform further simulations to identify the optimal dose to use for pulmonary MAC. This will be explored in the future, including prolonging infusion times. Here, our studies were mainly proof-of-concept of ceftazidime/avibactam effectiveness at clinically attainable doses.
In summary, the combination of ceftazidime/avibactam has activity against MAC. Its microbial kill was better than that of standard therapy drugs at currently recommended doses. The discovery that ceftazidime/avibactam is an anti-MAC agent creates the possibility for its potential use in the treatment of MAC in the future. 
